In situ induction of multivalent PD-L1 antibody secretion to enhance cancer immunotherapy

Biomaterials Science 2026

View at publisher
Authors: Li-Li Chen, Shi-Kun Zhou, Shui-Qing Jiang, Yi-Qun Sun, Xin-Yu Tan, Yi-Fang Chen, Yang Liu, Zi-Dong Lu, Cong‐Fei Xu
DOI: 10.1039/d5bm01896j
Cited by: 0
References: 34

Abstract

, which enables selective intratumoral secretion of MV-αPD-L1 in melanoma. This tumor-restricted antibody production induces potent, localized T-cell activation while minimizing off-target effects, thereby achieving superior therapeutic efficacy with an improved safety profile. Collectively, this strategy reprograms the tumor into a self-sustaining "antibody factory", providing a versatile and safe platform to amplify ICB efficacy through durable and tumor-specific immune modulation.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
Biomaterials Science
Volume
14
Issue
6
Pages
1544–1558
Publication date
1 January 2026
Language
EN